急性反復発作の世界市場レポート 2025年

急性反復発作市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.6％で54億4,000万米ドルに成長します。予測期間に予測される成長は、非侵襲的治療への需要の高まり、てんかん研究への投資の増加、ウェアラブル発作モニターの採用の高まり、神経学における遠隔医療の拡大、てんかん治療の改善を目的とした政府の取り組みに起因しています。予測期間における主な動向としては、発作予測におけるAIの採用、デジタルヘルスソリューションの統合、革新的治療のための臨床試験の拡大、てんかんの遺伝子治療の開発、新規薬剤製剤の創出などが挙げられます。

神経疾患の有病率の増加は、急性反復発作市場の成長を促進すると予想されます。神経疾患は脳、神経、脊髄に影響を及ぼし、運動、言語、認知、その他の身体機能の問題を引き起こします。これらの疾患の増加は、人口の高齢化によるところが大きく、高齢者は脳の退行性変化を受けやすく、アルツハイマー病、パーキンソン病、脳卒中などの疾患のリスクが高まります。急性反復発作は、神経障害の進行における重要な懸念事項であり、神経細胞の損傷、認知機能の低下、長期的な合併症の一因となるため、早期介入が非常に重要となります。例えば、アルツハイマー病協会によると、2023年までに65歳以上のアメリカ人の約670万人がアルツハイマー型認知症を患っており、2060年までにその数は1,380万人に増加すると予測されています。したがって、神経疾患の有病率の上昇は、急性反復発作市場の成長を促進する重要な要因です。

急性反復発作市場の主なプレーヤーは、薬物吸収を改善し、迅速な発作緩和を提供し、患者の利便性を高めるために、ベンゾジアゼピン頬側フィルムなどの革新的なドラッグデリバリー技術を開発しています。この頬側フィルムは、ベンゾジアゼピン系薬剤を含む薄い溶解可能なシートで、頬の内側に貼ることにより、口腔粘膜から速やかに吸収され、迅速な発作緩和をもたらします。薬物を血流に速やかに放出し、発作の持続時間と頻度を減少させることで、急性反復発作を管理するように設計されています。2024年12月、Aquestive Therapeutics Inc.は、同社の製品Libervant（ジアゼパム）頬側フィルムについて、米国食品医薬品局（FDA）から7年間の希少疾病用医薬品（ODE）としての独占権を取得しました。Libervantは、間欠性発作群および急性反復発作の急性期治療に使用されます。中枢神経抑制剤として作用し、ガンマアミノ酪酸（GABA）の作用を増強して発作活動を抑制します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性反復発作PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の急性反復発作市場：成長率分析
• 世界の急性反復発作市場の実績：規模と成長, 2019-2024
• 世界の急性反復発作市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性反復発作総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性反復発作市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベンゾジアゼピン
• 抗てんかん薬
• バルビツール酸
• その他の薬物の種類
• 世界の急性反復発作市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鼻腔内
• 直腸
• オーラル
• その他の投与経路
• 世界の急性反復発作市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ケア設定
• 世界の急性反復発作市場ベンゾジアゼピンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジアゼパム
• ロラゼパム
• ミダゾラム
• クロナゼパム
• アルプラゾラム
• 世界の急性反復発作市場抗てんかん薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レベチラセタム
• フェニトイン
• バルプロ酸
• カルバマゼピン
• ラモトリギン
• 世界の急性反復発作市場バルビツール酸系のサブセグメンテーション（種類別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェノバルビタール
• プリミドン
• 世界の急性反復発作市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 静脈内免疫グロブリン（IVIG）
• カンナビノイド

第7章 地域別・国別分析

• 世界の急性反復発作市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性反復発作市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性反復発作市場：競合情勢
• 急性反復発作市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Boehringer Ingelheim International GmbH
• Bausch Health US LLC.
• UCB S.A.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Zydus Lifesciences Limited
• Endo International plc
• Lupin Limited
• Amneal Pharmaceuticals LLC
• Aquestive Therapeutics Inc.
• Neurelis Inc.
• Grupo Ferrer Internacional S.A.
• UpsherSmith Laboratories LLC
• Aculys Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性反復発作市場2029：新たな機会を提供する国
• 急性反復発作市場2029：新たな機会を提供するセグメント
• 急性反復発作市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute repetitive seizures refer to a condition in which a person experiences multiple seizures within a short period, typically occurring within a 24-hour timeframe. These seizures often happen in quick succession, without a return to normal consciousness or baseline neurological function between episodes. They may be triggered by factors such as brain injury, infections, metabolic disturbances, or underlying neurological disorders.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main drug types used for managing acute repetitive seizures include benzodiazepines, antiepileptic drugs, barbiturates, and other related medications. Benzodiazepines are fast-acting drugs that help calm excessive brain activity, stopping acute seizures and preventing status epilepticus. These medications are administered via various routes, including intranasal, rectal, oral, and others. They are commonly used in hospitals, clinics, and home care settings by various end users.

The acute repetitive seizures market research report is one of a series of new reports from The Business Research Company that provides acute repetitive seizures market statistics, including the acute repetitive seizures industry global market size, regional shares, competitors with the acute repetitive seizures market share, detailed acute repetitive seizures market segments, market trends, and opportunities, and any further data you may need to thrive in the acute repetitive seizures industry. This acute repetitive seizures market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute repetitive seizures market size has grown rapidly in recent years. It will grow from $3.13 billion in 2024 to $3.51 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth observed during the historic period can be attributed to the rising prevalence of epilepsy, increasing awareness of seizure management, growth in the use of rescue medications, improvements in diagnostic capabilities, and the expansion of healthcare access.

The acute repetitive seizures market size is expected to see rapid growth in the next few years. It will grow to $5.44 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth projected for the forecast period can be attributed to the growing demand for non-invasive treatments, increasing investment in epilepsy research, the rising adoption of wearable seizure monitors, the expansion of telemedicine in neurology, and government initiatives aimed at improving epilepsy care. Key trends in the forecast period include the adoption of AI in seizure prediction, integration of digital health solutions, expanding clinical trials for innovative treatments, the development of gene therapies for epilepsy, and the creation of novel drug formulations.

The increasing prevalence of neurological disorders is expected to drive the growth of the acute repetitive seizures market. Neurological disorders affect the brain, nerves, or spinal cord, leading to issues with movement, speech, cognition, or other body functions. The rise in these conditions is largely due to an aging population, as older adults are more susceptible to degenerative brain changes, heightening the risk of diseases such as Alzheimer's, Parkinson's, and stroke. Acute repetitive seizures are a significant concern in the progression of neurological disorders, as they contribute to neuronal damage, cognitive decline, and long-term complications, making early intervention crucial. For example, according to the Alzheimer's Association, by 2023, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections estimating that number will increase to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is a key factor driving the growth of the acute repetitive seizures market.

Key players in the acute repetitive seizures market are developing innovative drug delivery technologies, such as the benzodiazepine buccal film, to improve drug absorption, provide rapid seizure relief, and enhance patient convenience. This buccal film, a thin dissolvable sheet containing benzodiazepine medication, is placed inside the cheek, where it quickly absorbs through the oral mucosa to deliver rapid relief. It is designed to manage acute repetitive seizures by swiftly releasing the medication into the bloodstream, reducing seizure duration and frequency. In December 2024, Aquestive Therapeutics Inc. received seven years of orphan drug exclusivity (ODE) from the U.S. Food and Drug Administration (FDA) for its product Libervant (diazepam) buccal film. Libervant is used for the acute treatment of intermittent seizure clusters and acute repetitive seizures. It acts as a central nervous system depressant, enhancing the effects of gamma-aminobutyric acid (GABA) to reduce seizure activity.

In January 2022, Aculys Pharma, Inc., a Japanese biopharmaceutical company specializing in neurological treatments, entered into a partnership with Neurelis, Inc. This collaboration aims to expand access to innovative therapies for neurological conditions, particularly seizure management. The companies secured licensing rights for advanced therapies, such as VALTOCO, a nasal spray used to manage seizure clusters and acute repetitive seizures. Neurelis, Inc., based in the U.S., focuses on neurology and psychiatry treatments, further enhancing their ability to deliver targeted therapies for patients suffering from these debilitating conditions.

Major players in the acute repetitive seizures market are Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bausch Health US LLC., UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Zydus Lifesciences Limited, Endo International plc, Lupin Limited, Amneal Pharmaceuticals LLC, Aquestive Therapeutics Inc., Neurelis Inc., Grupo Ferrer Internacional S.A., UpsherSmith Laboratories LLC, Aculys Pharma Inc.

North America was the largest region in the acute repetitive seizures market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute repetitive seizures report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Acute Repetitive Seizures market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute repetitive seizures market consists of revenues earned by entities by providing services such as emergency medical services, hospital-based treatment, telemedicine and remote monitoring, specialty pharmacy services, seizure action plan development. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute repetitive seizures market also includes sales of intranasal rescue medications, rectal diazepam gel, anticonvulsants, and wearable seizure detection devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Repetitive Seizures Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute repetitive seizures market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute repetitive seizures ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute repetitive seizures market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Benzodiazepines; Antiepileptic Drugs; Barbiturates; Other Drug Types
• 2) By Route Of Administration: Intranasal; Rectal; Oral; Other Routes Of Administrations
• 3) By End User: Hospitals; Clinics; Home Care Settings
• Subsegments:
• 1) By Benzodiazepines: Diazepam; Lorazepam; Midazolam; Clonazepam; Alprazolam
• 2) By Antiepileptic Drugs: Levetiracetam; Phenytoin; Valproate; Carbamazepine; Lamotrigine
• 3) By Barbiturates: Phenobarbital; Primidone
• 4) By Other Drug Types: Corticosteroids; Intravenous Immunoglobulins (IVIG); Cannabinoids
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Repetitive Seizures Market Characteristics

3. Acute Repetitive Seizures Market Trends And Strategies

4. Acute Repetitive Seizures Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Acute Repetitive Seizures Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Repetitive Seizures PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Repetitive Seizures Market Growth Rate Analysis
• 5.4. Global Acute Repetitive Seizures Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Repetitive Seizures Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Repetitive Seizures Total Addressable Market (TAM)

6. Acute Repetitive Seizures Market Segmentation

• 6.1. Global Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Benzodiazepines
• Antiepileptic Drugs
• Barbiturates
• Other Drug Types
• 6.2. Global Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intranasal
• Rectal
• Oral
• Other Routes Of Administrations
• 6.3. Global Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care Settings
• 6.4. Global Acute Repetitive Seizures Market, Sub-Segmentation Of Benzodiazepines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diazepam
• Lorazepam
• Midazolam
• Clonazepam
• Alprazolam
• 6.5. Global Acute Repetitive Seizures Market, Sub-Segmentation Of Antiepileptic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levetiracetam
• Phenytoin
• Valproate
• Carbamazepine
• Lamotrigine
• 6.6. Global Acute Repetitive Seizures Market, Sub-Segmentation Of Barbiturates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phenobarbital
• Primidone
• 6.7. Global Acute Repetitive Seizures Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Intravenous Immunoglobulins (IVIG)
• Cannabinoids

7. Acute Repetitive Seizures Market Regional And Country Analysis

• 7.1. Global Acute Repetitive Seizures Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Repetitive Seizures Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Repetitive Seizures Market

• 8.1. Asia-Pacific Acute Repetitive Seizures Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Repetitive Seizures Market

• 9.1. China Acute Repetitive Seizures Market Overview
• 9.2. China Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Repetitive Seizures Market

• 10.1. India Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Repetitive Seizures Market

• 11.1. Japan Acute Repetitive Seizures Market Overview
• 11.2. Japan Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Repetitive Seizures Market

• 12.1. Australia Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Repetitive Seizures Market

• 13.1. Indonesia Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Repetitive Seizures Market

• 14.1. South Korea Acute Repetitive Seizures Market Overview
• 14.2. South Korea Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Repetitive Seizures Market

• 15.1. Western Europe Acute Repetitive Seizures Market Overview
• 15.2. Western Europe Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Repetitive Seizures Market

• 16.1. UK Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Repetitive Seizures Market

• 17.1. Germany Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Repetitive Seizures Market

• 18.1. France Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Repetitive Seizures Market

• 19.1. Italy Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Repetitive Seizures Market

• 20.1. Spain Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Repetitive Seizures Market

• 21.1. Eastern Europe Acute Repetitive Seizures Market Overview
• 21.2. Eastern Europe Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Repetitive Seizures Market

• 22.1. Russia Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Repetitive Seizures Market

• 23.1. North America Acute Repetitive Seizures Market Overview
• 23.2. North America Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Repetitive Seizures Market

• 24.1. USA Acute Repetitive Seizures Market Overview
• 24.2. USA Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Repetitive Seizures Market

• 25.1. Canada Acute Repetitive Seizures Market Overview
• 25.2. Canada Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Repetitive Seizures Market

• 26.1. South America Acute Repetitive Seizures Market Overview
• 26.2. South America Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Repetitive Seizures Market

• 27.1. Brazil Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Repetitive Seizures Market

• 28.1. Middle East Acute Repetitive Seizures Market Overview
• 28.2. Middle East Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Repetitive Seizures Market

• 29.1. Africa Acute Repetitive Seizures Market Overview
• 29.2. Africa Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Repetitive Seizures Market Competitive Landscape And Company Profiles

• 30.1. Acute Repetitive Seizures Market Competitive Landscape
• 30.2. Acute Repetitive Seizures Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Acute Repetitive Seizures Market Other Major And Innovative Companies

• 31.1. Boehringer Ingelheim International GmbH
• 31.2. Bausch Health US LLC.
• 31.3. UCB S.A.
• 31.4. Eisai Co. Ltd.
• 31.5. Sun Pharmaceutical Industries Ltd.
• 31.6. Hikma Pharmaceuticals PLC
• 31.7. Zydus Lifesciences Limited
• 31.8. Endo International plc
• 31.9. Lupin Limited
• 31.10. Amneal Pharmaceuticals LLC
• 31.11. Aquestive Therapeutics Inc.
• 31.12. Neurelis Inc.
• 31.13. Grupo Ferrer Internacional S.A.
• 31.14. UpsherSmith Laboratories LLC
• 31.15. Aculys Pharma Inc.

32. Global Acute Repetitive Seizures Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Repetitive Seizures Market

34. Recent Developments In The Acute Repetitive Seizures Market

35. Acute Repetitive Seizures Market High Potential Countries, Segments and Strategies

• 35.1 Acute Repetitive Seizures Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Repetitive Seizures Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Repetitive Seizures Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34744_Acute_Repetitive_Seizures_GMR_2025